Landscape Capital Management L.L.C. Decreases Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Landscape Capital Management L.L.C. trimmed its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 25.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 198,019 shares of the company's stock after selling 68,638 shares during the quarter. Hims & Hers Health makes up 0.5% of Landscape Capital Management L.L.C.'s investment portfolio, making the stock its 27th largest position. Landscape Capital Management L.L.C. owned approximately 0.09% of Hims & Hers Health worth $4,788,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Crewe Advisors LLC purchased a new position in Hims & Hers Health during the 4th quarter worth approximately $28,000. Raleigh Capital Management Inc. grew its position in shares of Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after acquiring an additional 1,100 shares during the last quarter. Blume Capital Management Inc. increased its holdings in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after acquiring an additional 600 shares during the period. Smartleaf Asset Management LLC raised its position in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock valued at $36,000 after purchasing an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC acquired a new stake in Hims & Hers Health during the 4th quarter worth $38,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Hims & Hers Health Price Performance

HIMS stock traded down $0.35 during midday trading on Wednesday, hitting $25.75. The stock had a trading volume of 9,513,296 shares, compared to its average volume of 22,777,082. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98. The firm has a market cap of $5.72 billion, a PE ratio of 58.44 and a beta of 1.65. The company's 50-day moving average price is $39.53 and its 200 day moving average price is $30.15.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The firm had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on HIMS shares. BTIG Research started coverage on shares of Hims & Hers Health in a research note on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price objective on the stock. Needham & Company LLC boosted their price target on Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research report on Tuesday, February 25th. Morgan Stanley cut Hims & Hers Health from an "overweight" rating to an "equal weight" rating and increased their price objective for the stock from $42.00 to $60.00 in a research report on Tuesday, February 18th. Truist Financial boosted their target price on Hims & Hers Health from $24.00 to $39.00 and gave the company a "hold" rating in a report on Wednesday, February 26th. Finally, Canaccord Genuity Group upped their price target on Hims & Hers Health from $38.00 to $68.00 and gave the stock a "buy" rating in a research note on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $37.31.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 36,460 shares of the stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $27.09, for a total transaction of $987,701.40. Following the completion of the sale, the chief executive officer now owns 27,918 shares of the company's stock, valued at approximately $756,298.62. This represents a 56.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Oluyemi Okupe sold 11,581 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $29.26, for a total transaction of $338,860.06. Following the completion of the transaction, the chief financial officer now owns 124,104 shares in the company, valued at $3,631,283.04. The trade was a 8.54 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 809,806 shares of company stock valued at $30,923,658. Insiders own 17.71% of the company's stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.